Vandetanib
This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.
Peso molecular
475,4000 g/mol
LogP
4,90
TPSA
59,50 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
InChI
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
Molecular Formula
C22H24BrFN4O2
HBD / HBA
1 / 7
Enlaces Rotables
6
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This targeted therapy blocks multiple receptors (VEGFR, EGFR, and RET) involved in tumor growth and blood vessel formation, and is used to treat symptomatic or progressive medullary thyroid cancer that cannot be surgically removed. It is taken as a daily oral tablet. It can cause a serious prolongation of the heart's electrical rhythm (QT prolongation), requiring regular heart monitoring.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Vandetanib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL24828. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3081361. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vandetanib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vandetanib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vandetanib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vandetanib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vandetanib"></drugfyi-drug>